Sleep disorders. Study of its prevalence and treatment from the Community Pharmacy
DOI:
https://doi.org/10.60103/phc.v27.e880Keywords:
insomnia; pharmacist; community pharmacy; self-medicationAbstract
Introduction: Insomnia, one of the most prevalent sleep disorders in the west countries is often a secondary manifestation of other pathologies. Although there are numerous pharmacological and non-pharmacological treatment options available, the desired treatment outcome is not always achieved. In this context, the aim of this study was to analyze the conditions of use of drugs and phytopharmaceuticals used in the treatment of insomnia.
Methods: A cross-sectional descriptive observational study was carried out with 64 patients recruited in 2 pharmacies in the Community of Madrid. A questionnaire was prepared and distributed among the study participants for them to fill it in voluntarily, autonomously and anonymously through the platform Forms Office.
Results: The study showed a higher participation of women than men (73% vs 27%). Although the mean age was 60 years, a high participation of young people was observed. It should be noted that 65% of the participants used an non-prescription drugs and only 45% of them stated that they had received pharmaceutical advice. Although 98% of the participants had adequate knowledge about their treatment, they were unaware of the potential adverse effects to which they could be exposed.
Conclusions: Many patients with sleep disorders self-medicate with drugs/phytopharmaceuticals without knowing the safety and duration of treatment. Therefore, pharmacist advice during dispensing is essential to ensure the effectiveness and safety of the treatment.
Downloads
References
Ohayon MM, Sagales T. Prevalence of insomnia and sleep characteristics in the general population of Spain. Sleep Med. 2010;11(10):1010–8. DOI: 10.1016/j.sleep.2010.02.018.
Fernández Moriano C. Trastornos del sueño: abordaje farmacoterapéutico. Panorama actual del medicamento. 2021;45(441):151–76. Disponible en https://dialnet.unirioja.es/servlet/articulo?codigo=7853357
Carretero Accame ME. Plantas medicinales para alteraciones del sueño, ansiedad y depresión (V): Valeriana. Panorama Actual Med. 2013;37(361):217–22. Disponible en https://dialnet.unirioja.es/servlet/articulo?codigo=4221426
Díaz-García Ó, Dévora-Figueroa C, Díez González LM, Fernández del Pozo de Salamanca, MB. Farmacología del sistema nervioso. En: Trastornos neurológicos y neuropsiquiátricos. Consejo General de Colegios Oficiales de Farmacéuticos. 2019;1–120.
Cuéllar-Rodríguez Santiago. Insomnio. Panorama Actual Med. 2014;38(371):133–46.
Madari S, Golebiowski R, Mansukhani MP, Prakash Kolla B. Pharmacological Management of Insomnia. Neurotherapeutics. 2021; 18:44–52. DOI: https://doi.org/10.1007/s13311-021-01010-z
Álamo González C, Alonso Álvarez ML, Cañellas Dols F, Martín Águeda B, Pérez Díaz H, Romero Santo-Tomás O, Terán Santos J. Pautas de actuación y seguimiento: Insomnio. 1ª Edición. International Marketing & Communication, S.A. (IM&C), 2015.
Morin CM, LeBlanc M, Bélanger L, Ivers H, Mérette C, Savard J. Prevalence of insomnia and its treatment in Canada. Canadian Journal of Psychiatry. 2011;56(9):540–8. DOI: 10.1177/070674371105600905.
Molina-Martín JD, Campos Abraham P, Andrade Rosa C. Terapéutica de los trastornos de ansiedad y del sueño. Trastornos neurológicos y neuropsiquiátricos Madrid: Consejo General de Colegios Oficiales de Farmacéuticos. 2019;219–46.
Burman D. Sleep Disorders: Insomnia. FP Essent. 2017;460:22–8. Disponible en: https://www.researchgate.net/publication/320854026_Sleep_Disorders_Insomnia
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS One. 2013;8(5):63773. DOI: 10.1371/journal.pone.0063773.
Lechevallier N, Fourrier A, Berr C. Benzodiazepine use in the elderly: the EVA Study. Rev Epidemiol Sante Publique. 2003;51(3):317–26. Disponible en: https://www.researchgate.net/publication/10412131_Benzodiazepine_use_in_the_elderly_the_EVA_Study
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mariana Vázquez-del Real, Marta Gil Ortega, Beatriz Somoza Hernández
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Pharmaceutical Care España se publica bajo una licencia «Creative Commons, Reconocimiento, No Comercial y Compartir Igual 4.0 Internacional» (CC BY-NC-SA 4.0)», que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista (con excepción de los usos comerciales).
Los autores que publican en esta revista están de acuerdo con los siguientes términos:a) Los autores conservan los derechos de autor (derechos morales) y garantizan a la revista el derecho de ser el primer soporte documental publicado del trabajo.
b) Se permite y anima a los autores a difundir la versión del trabajo revisado por pares y aceptada para su publicación (por ejemplo, en repositorios institucionales o temáticos), recomendando hacerlo con la versión final del editor “pdf”, “html” o “xml”).
